MiNK Therapeutics (INKT) Short Interest Ratio & Short Volume → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free INKT Stock Alerts $0.91 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media MiNK Therapeutics Short Interest DataCurrent Short Volume46,500 sharesPrevious Short Volume41,300 sharesChange Vs. Previous Month+12.59%Dollar Volume Sold Short$41,594.25Short Interest Ratio / Days to Cover0.8Last Record DateMarch 15, 2024Outstanding Shares34,699,000 sharesFloat Size9,790,000 sharesShort Percent of Float0.47%Today's Trading Volume35,116 sharesAverage Trading Volume51,559 sharesToday's Volume Vs. Average68% Short Selling MiNK Therapeutics ? Sign up to receive the latest short interest report for MiNK Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatINKT Short Interest Over TimeINKT Days to Cover Over TimeINKT Percentage of Float Shorted Over Time Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… MiNK Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/202446,500 shares $41,594.25 +12.6%0.5%0.8 $0.89 2/29/202441,300 shares $38,049.69 -76.4%0.4%0.7 $0.92 2/15/2024175,100 shares $162,843.00 -7.6%1.8%3.4 $0.93 1/31/2024189,400 shares $163,831.00 +8.3%2.0%3.8 $0.87 1/15/2024174,900 shares $172,976.10 -1.7%1.8%3.8 $0.99 12/31/2023178,000 shares $190,460.00 +237.8%1.9%4.6 $1.07 Get the Latest News and Ratings for INKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/15/202352,700 shares $53,754.00 -66.3%0.6%1.2 $1.02 11/30/2023156,400 shares $164,220.00 +2.4%1.6%3.9 $1.05 11/15/2023152,700 shares $155,754.00 -19.7%1.6%3.4 $1.02 10/31/2023190,100 shares $193,902.00 +11.7%2.0%3.6 $1.02 10/15/2023170,200 shares $187,220.00 +6.7%1.8%3 $1.10 9/30/2023159,500 shares $175,450.00 -11.7%1.8%2.4 $1.10 9/15/2023180,600 shares $232,974.00 -7.7%1.9%2.5 $1.29 8/31/2023195,700 shares $283,765.00 -1.0%2.1%1.9 $1.45 8/15/2023197,600 shares $337,896.00 -31.4%2.0%1.8 $1.71 7/31/2023288,000 shares $538,560.00 +6.9%3.0%2.1 $1.87 7/15/2023269,500 shares $493,185.00 +1.7%2.8%1.4 $1.83 6/30/2023264,900 shares $556,290.00 +68.5%2.7%1.4 $2.10 6/15/2023157,200 shares $377,280.00 +2.0%1.6%0.9 $2.40 5/31/2023154,100 shares $271,216.00 -14.6%1.7%1.2 $1.76 5/15/2023180,500 shares $305,045.00 +70.4%1.9%1.5 $1.69 4/30/2023105,900 shares $189,561.00 +117.5%1.1%1.1 $1.79 4/15/202348,700 shares $107,627.00 +34.2%1.1%2.8 $2.21 3/31/202336,300 shares $68,788.50 -14.0%0.8%3.2 $1.90 3/15/202342,200 shares $84,822.00 +92.7%1.0%3.6 $2.01 2/28/202321,900 shares $44,457.00 -60.9%0.5%2.2 $2.03 2/15/202356,000 shares $112,560.00 -19.4%1.3%4.6 $2.01 1/31/202369,500 shares $159,155.00 -10.6%1.6%3.2 $2.29 1/15/202377,700 shares $183,372.00 -15.2%1.7%3.4 $2.36 12/30/202291,600 shares $239,076.00 -7.0%2.0%3.9 $2.61 12/15/202298,500 shares $217,685.00 -34.9%2.1%4 $2.21 11/30/2022151,400 shares $401,210.00 -7.4%3.3%5.2 $2.65 11/15/2022163,500 shares $501,667.05 +24.0%3.5%4.6 $3.07 10/31/2022131,900 shares $287,542.00 +3.2%2.8%0.3 $2.18 10/15/2022127,800 shares $241,542.00 -0.8%2.8%0.3 $1.89 9/30/2022128,800 shares $271,768.00 +25.1%2.8%0.3 $2.11 9/15/2022103,000 shares $269,860.00 -46.1%2.2%0.2 $2.62 8/31/2022191,200 shares $502,856.00 +15.3%4.2%0.4 $2.63 8/15/2022165,800 shares $563,720.00 +400.9%3.7%0.4 $3.40 7/31/202233,100 shares $43,361.00 +0.3%0.8%0.8 $1.31“The Stock Market’s Bull Run is Far from Over” -Barrons (Ad)Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… INKT Short Interest - Frequently Asked Questions What is MiNK Therapeutics' current short interest? Short interest is the volume of MiNK Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 15th, traders have sold 46,500 shares of INKT short. 0.47% of MiNK Therapeutics' shares are currently sold short. Learn More on MiNK Therapeutics' current short interest. What is a good short interest ratio for MiNK Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. INKT shares currently have a short interest ratio of 1.0. Learn More on MiNK Therapeutics's short interest ratio. What is a good short interest percentage for MiNK Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.47% of MiNK Therapeutics' floating shares are currently sold short. Is MiNK Therapeutics' short interest increasing or decreasing? MiNK Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 46,500 shares, an increase of 12.6% from the previous total of 41,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is MiNK Therapeutics' float size? MiNK Therapeutics currently has issued a total of 34,699,000 shares. Some of MiNK Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. MiNK Therapeutics currently has a public float of 9,790,000 shares. How does MiNK Therapeutics' short interest compare to its competitors? 0.47% of MiNK Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to MiNK Therapeutics: Brainstorm Cell Therapeutics Inc. (1.74%), Gamida Cell Ltd. (10.38%), Surrozen, Inc. (0.24%), Aptose Biosciences Inc. (0.54%), IN8bio, Inc. (0.29%), CASI Pharmaceuticals, Inc. (2.22%), Cyclo Therapeutics, Inc. (0.89%), OKYO Pharma Limited (0.28%), Pluri Inc. (0.52%), ZIVO Bioscience, Inc. (4.24%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks. What does it mean to sell short MiNK Therapeutics stock? Short selling INKT is an investing strategy that aims to generate trading profit from MiNK Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against MiNK Therapeutics? A short squeeze for MiNK Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of INKT, which in turn drives the price of the stock up even further. How often is MiNK Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INKT, twice per month. The most recent reporting period available is March, 15 2024. More Short Interest Resources from MarketBeat Related Companies: BCLI Short Interest GMDA Short Interest SRZN Short Interest APTO Short Interest INAB Short Interest CASI Short Interest CYTH Short Interest OKYO Short Interest PLUR Short Interest ZIVO Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:INKT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchThe 3rd Revolution in WarfareWeiss Ratings